Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Fig. 2

Change in weekly migraine days in A) participants aged ≥60 years and B) overall population. LSM, least-squares mean; LSMD, least-squares mean differences; SE, standard error. Data shown are the LSM changes from baseline in the weekly average number of migraine days over the first 4 weeks of double-blind treatment. aP < 0.01 vs placebo. bP < 0.05 vs placebo. cP < 0.0001 vs placebo

Back to article page